Former Stanford employee guilty of illegally accessing, altering breast cancer database
A former employee of Stanford University was found guilty of accessing a clinical research database for a multisite breast ...
Sierra Sun Times3h
Former Stanford Research Coordinator Convicted for Unlawfully Accessing and Altering Breast Cancer Study Database Hours After Being Fired
Former Stanford Research Coordinator Convicted for Unlawfully Accessing and Altering Breast Cancer Study Database Hours After ...
Blood Tests And Breastmilk: Why Investors Are Betting Big On Female Biology
As we enter 2025, the confluence of scientific advancement, market opportunity and industry validation suggests women's ...
FierceBiotech13d
Genentech archives diversity reports amid site update, examines ‘potential implications of executive orders’
Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversity reports as the company’s diversity and ...
FiercePharma6d
Genentech, Novartis join forces to raise awareness of food allergies’ impact on families
Genentech and Novartis have teamed up with Food Allergy Research & Education (FARE) to enhance the safety of children with ...
Crime and Public Safety
A jury found Naheed Mangi replaced patient medical data with erroneous information, insults about former boss.
Pharm Exec5d
Genentech, Novartis, and FARE Partner for Food Allergy Educational Campaign
The campaign is based on the results of a survey that reveals the experiences of patients and caregivers in their communities ...
Hosted on MSN18d
Genentech eyes lupus market for Gazyva with positive Phase III data readout
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company targets the billion-dollar lupus market for its CD20-targeting drug Gazyva ...
Business Wire14d
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New ...
If this biotech CEO succeeds millions of cancer patients could benefit
If this CEO succeeds N-Power could save millions of dollars and lives in the fight against cancer. "The impact for cancer ...
Hosted on MSN28d
Genentech’s Itovebi combo hits overall survival endpoint in HER2- breast cancer
Genentech Therapeutics’s Phase III trial of Itovebi in patients with certain types of metastatic breast cancer has met the gold standard oncology endpoint of overall survival (OS) while also ...
Business Wire22d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ...